Do analysts prefer NNNN or COGT?

Cogent Biosciences has a consensus target price of $45.90, suggesting a potential upside of 17.45%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cogent Biosciences is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cogent Biosciences 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 2.85

Which has preferable earnings and valuation, NNNN or COGT?

Anbio Biotechnology has higher revenue and earnings than Cogent Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 157.86 $6.40M N/A N/A Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A

Is NNNN or COGT more profitable?

Anbio Biotechnology's return on equity of 0.00% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Anbio Biotechnology N/A N/A N/A Cogent Biosciences N/A -104.27% -54.64%

Do analysts rate SRRK or NNNN?

Scholar Rock currently has a consensus target price of $56.00, suggesting a potential upside of 5.94%. Given Scholar Rock's stronger consensus rating and higher probable upside, analysts plainly believe Scholar Rock is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scholar Rock 1 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 4 Strong Buy rating(s) 3.12 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable valuation & earnings, SRRK or NNNN?

Anbio Biotechnology has higher revenue and earnings than Scholar Rock. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.59 N/A Anbio Biotechnology $8.65M 157.86 $6.40M N/A N/A

Is SRRK or NNNN more profitable?

Anbio Biotechnology's return on equity of 0.00% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% Anbio Biotechnology N/A N/A N/A

Do analysts prefer NNNN or CNTA?

Centessa Pharmaceuticals has a consensus target price of $41.33, indicating a potential upside of 2.06%. Given Centessa Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Centessa Pharmaceuticals is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Centessa Pharmaceuticals 1 Sell rating(s) 9 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.21

Which has higher valuation and earnings, NNNN or CNTA?

Anbio Biotechnology has higher revenue and earnings than Centessa Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 157.86 $6.40M N/A N/A Centessa Pharmaceuticals N/A N/A -$197.53M -$1.79 N/A

Is NNNN or CNTA more profitable?

Anbio Biotechnology's return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Anbio Biotechnology N/A N/A N/A Centessa Pharmaceuticals N/A -60.37% -44.17%

Do analysts prefer NNNN or XENE?

Xenon Pharmaceuticals has a consensus price target of $77.20, indicating a potential upside of 13.10%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Xenon Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has preferable earnings & valuation, NNNN or XENE?

Anbio Biotechnology has higher revenue and earnings than Xenon Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 157.86 $6.40M N/A N/A Xenon Pharmaceuticals $7.50M 879.83 -$345.91M -$4.70 N/A

Is NNNN or XENE more profitable?

Anbio Biotechnology's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Anbio Biotechnology N/A N/A N/A Xenon Pharmaceuticals N/A -49.23% -46.42%

Do analysts prefer NNNN or CGON?

CG Oncology has a consensus target price of $81.73, suggesting a potential upside of 13.75%. Given CG Oncology's stronger consensus rating and higher possible upside, analysts clearly believe CG Oncology is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 CG Oncology 1 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has better earnings & valuation, NNNN or CGON?

Anbio Biotechnology has higher revenue and earnings than CG Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 157.86 $6.40M N/A N/A CG Oncology $5.07M 1,249.72 -$160.99M -$2.33 N/A

Is NNNN or CGON more profitable?

Anbio Biotechnology's return on equity of 0.00% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Anbio Biotechnology N/A N/A N/A CG Oncology N/A -23.33% -22.24%

Anbio Biotechnology (NNNN) Competitors

$9.49 -0.11 (-1.15%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$9.44 -0.04 (-0.47%)

As of 07/17/2026 04:10 PM Eastern

Compare

NNNN vs. COGT, SRRK, CNTA, XENE, and CGON

Should you buy Anbio Biotechnology stock or one of its competitors? MarketBeat compares Anbio Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anbio Biotechnology include Cogent Biosciences (COGT), Scholar Rock (SRRK), Centessa Pharmaceuticals (CNTA), Xenon Pharmaceuticals (XENE), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry.

How does Anbio Biotechnology compare to Cogent Biosciences?

Anbio Biotechnology (NASDAQ:NNNN) and Cogent Biosciences (NASDAQ:COGT) are both pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Cogent Biosciences has a consensus target price of $45.90, suggesting a potential upside of 17.45%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cogent Biosciences is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85

In the previous week, Cogent Biosciences had 2 more articles in the media than Anbio Biotechnology. MarketBeat recorded 2 mentions for Cogent Biosciences and 0 mentions for Anbio Biotechnology. Cogent Biosciences' average media sentiment score of 0.85 beat Anbio Biotechnology's score of 0.00 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Anbio Biotechnology	Neutral
Cogent Biosciences	Positive

Anbio Biotechnology has a beta of 5.15, indicating that its stock price is 415% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

Anbio Biotechnology has higher revenue and earnings than Cogent Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	157.86	$6.40M	N/A	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Anbio Biotechnology's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Cogent Biosciences	N/A	-104.27%	-54.64%

Summary

Cogent Biosciences beats Anbio Biotechnology on 6 of the 11 factors compared between the two stocks.

How does Anbio Biotechnology compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Anbio Biotechnology (NASDAQ:NNNN) are both pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Scholar Rock currently has a consensus target price of $56.00, suggesting a potential upside of 5.94%. Given Scholar Rock's stronger consensus rating and higher probable upside, analysts plainly believe Scholar Rock is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Scholar Rock had 2 more articles in the media than Anbio Biotechnology. MarketBeat recorded 2 mentions for Scholar Rock and 0 mentions for Anbio Biotechnology. Scholar Rock's average media sentiment score of 0.77 beat Anbio Biotechnology's score of 0.00 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Overall Sentiment
Scholar Rock	Positive
Anbio Biotechnology	Neutral

91.1% of Scholar Rock shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Scholar Rock has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.15, meaning that its stock price is 415% more volatile than the broader market.

Anbio Biotechnology has higher revenue and earnings than Scholar Rock.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Anbio Biotechnology	$8.65M	157.86	$6.40M	N/A	N/A

Anbio Biotechnology's return on equity of 0.00% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Anbio Biotechnology	N/A	N/A	N/A

Summary

Scholar Rock beats Anbio Biotechnology on 8 of the 13 factors compared between the two stocks.

How does Anbio Biotechnology compare to Centessa Pharmaceuticals?

Anbio Biotechnology (NASDAQ:NNNN) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

Anbio Biotechnology's return on equity of 0.00% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

Centessa Pharmaceuticals has a consensus target price of $41.33, indicating a potential upside of 2.06%. Given Centessa Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Centessa Pharmaceuticals is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

Anbio Biotechnology has higher revenue and earnings than Centessa Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	157.86	$6.40M	N/A	N/A
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A

82.0% of Centessa Pharmaceuticals shares are owned by institutional investors. 4.1% of Centessa Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Anbio Biotechnology has a beta of 5.15, meaning that its share price is 415% more volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

In the previous week, Anbio Biotechnology's average media sentiment score of 0.00 equaled Centessa Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Anbio Biotechnology	Neutral
Centessa Pharmaceuticals	Neutral

Summary

Anbio Biotechnology and Centessa Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

How does Anbio Biotechnology compare to Xenon Pharmaceuticals?

Anbio Biotechnology (NASDAQ:NNNN) and Xenon Pharmaceuticals (NASDAQ:XENE) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Anbio Biotechnology has a beta of 5.15, meaning that its share price is 415% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Anbio Biotechnology has higher revenue and earnings than Xenon Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	157.86	$6.40M	N/A	N/A
Xenon Pharmaceuticals	$7.50M	879.83	-$345.91M	-$4.70	N/A

Xenon Pharmaceuticals has a consensus price target of $77.20, indicating a potential upside of 13.10%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Xenon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	2 Strong Buy rating(s)	3.00

95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 2.9% of Xenon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Anbio Biotechnology's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Xenon Pharmaceuticals	N/A	-49.23%	-46.42%

In the previous week, Xenon Pharmaceuticals had 5 more articles in the media than Anbio Biotechnology. MarketBeat recorded 5 mentions for Xenon Pharmaceuticals and 0 mentions for Anbio Biotechnology. Xenon Pharmaceuticals' average media sentiment score of 1.49 beat Anbio Biotechnology's score of 0.00 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Anbio Biotechnology	Neutral
Xenon Pharmaceuticals	Positive

Summary

Xenon Pharmaceuticals beats Anbio Biotechnology on 9 of the 14 factors compared between the two stocks.

How does Anbio Biotechnology compare to CG Oncology?

Anbio Biotechnology (NASDAQ:NNNN) and CG Oncology (NASDAQ:CGON) are both pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Anbio Biotechnology's return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
CG Oncology	N/A	-23.33%	-22.24%

Anbio Biotechnology has higher revenue and earnings than CG Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	157.86	$6.40M	N/A	N/A
CG Oncology	$5.07M	1,249.72	-$160.99M	-$2.33	N/A

In the previous week, CG Oncology had 9 more articles in the media than Anbio Biotechnology. MarketBeat recorded 9 mentions for CG Oncology and 0 mentions for Anbio Biotechnology. CG Oncology's average media sentiment score of 0.78 beat Anbio Biotechnology's score of 0.00 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Anbio Biotechnology	Neutral
CG Oncology	Positive

CG Oncology has a consensus target price of $81.73, suggesting a potential upside of 13.75%. Given CG Oncology's stronger consensus rating and higher possible upside, analysts clearly believe CG Oncology is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

26.6% of CG Oncology shares are held by institutional investors. 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Anbio Biotechnology has a beta of 5.15, meaning that its stock price is 415% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market.

Summary

CG Oncology beats Anbio Biotechnology on 8 of the 13 factors compared between the two stocks.

Get Anbio Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NNNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NNNN vs. The Competition

Export

Metric	Anbio Biotechnology	In Vitro, In Vivo Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.37B	$386.72M	$4.41B	$12.29B
Dividend Yield	N/A	N/A	37.90%	9.34%
P/E Ratio	N/A	N/A	23.70	23.92
Price / Sales	157.86	97.83	134.89	75.61
Price / Cash	213.23	213.23	164.16	60.41
Price / Book	45.19	22.93	12.18	6.18
Net Income	$6.40M	-$18.48M	$121.47M	$332.29M
7 Day Performance	1.06%	-4.09%	-1.12%	-2.05%
1 Month Performance	-42.97%	-20.85%	-2.65%	-2.18%
1 Year Performance	N/A	-60.00%	9.79%	17.67%

Anbio Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NNNN Anbio Biotechnology	0.2957 of 5 stars	$9.49 -1.1%	N/A	N/A	$1.37B	$8.65M	N/A	27	Gap Up
COGT Cogent Biosciences	2.0516 of 5 stars	$39.10 -2.3%	$43.73 +11.8%	+212.9%	$6.65B	N/A	N/A	80
SRRK Scholar Rock	2.0484 of 5 stars	$55.66 -1.6%	$56.00 +0.6%	+29.8%	$6.62B	N/A	N/A	140	Positive News
CNTA Centessa Pharmaceuticals	0.9421 of 5 stars	$40.50 flat	$41.33 +2.1%	N/A	$6.27B	N/A	N/A	200
XENE Xenon Pharmaceuticals	2.4793 of 5 stars	$64.85 +2.3%	$77.20 +19.1%	+116.1%	$6.26B	$7.50M	N/A	210	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NNNN) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anbio Biotechnology (NNNN) Competitors

NNNN vs. COGT, SRRK, CNTA, XENE, and CGON

How does Anbio Biotechnology compare to Cogent Biosciences?

Summary

How does Anbio Biotechnology compare to Scholar Rock?

Summary

How does Anbio Biotechnology compare to Centessa Pharmaceuticals?

Summary

How does Anbio Biotechnology compare to Xenon Pharmaceuticals?

Summary

How does Anbio Biotechnology compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNNN vs. The Competition

Anbio Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anbio Biotechnology (NNNN) Competitors

NNNN vs. COGT, SRRK, CNTA, XENE, and CGON

How does Anbio Biotechnology compare to Cogent Biosciences?

Do analysts prefer NNNN or COGT?

Does the media favor NNNN or COGT?

Which has more volatility & risk, NNNN or COGT?

Which has preferable earnings and valuation, NNNN or COGT?

Is NNNN or COGT more profitable?

Summary

How does Anbio Biotechnology compare to Scholar Rock?

Do analysts rate SRRK or NNNN?

Does the media prefer SRRK or NNNN?

Do insiders and institutionals hold more shares of SRRK or NNNN?

Which has more risk and volatility, SRRK or NNNN?

Which has preferable valuation & earnings, SRRK or NNNN?

Is SRRK or NNNN more profitable?

Summary

How does Anbio Biotechnology compare to Centessa Pharmaceuticals?

Is NNNN or CNTA more profitable?

Do analysts prefer NNNN or CNTA?

Which has higher valuation and earnings, NNNN or CNTA?

Do insiders & institutionals have more ownership in NNNN or CNTA?

Which has more risk and volatility, NNNN or CNTA?

Does the media favor NNNN or CNTA?

Summary

How does Anbio Biotechnology compare to Xenon Pharmaceuticals?

Which has more volatility and risk, NNNN or XENE?

Which has preferable earnings & valuation, NNNN or XENE?

Do analysts prefer NNNN or XENE?

Do institutionals and insiders have more ownership in NNNN or XENE?

Is NNNN or XENE more profitable?

Does the media favor NNNN or XENE?

Summary

How does Anbio Biotechnology compare to CG Oncology?

Is NNNN or CGON more profitable?

Which has better earnings & valuation, NNNN or CGON?

Does the media favor NNNN or CGON?

Do analysts prefer NNNN or CGON?

Do insiders & institutionals believe in NNNN or CGON?

Which has more volatility & risk, NNNN or CGON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNNN vs. The Competition

Anbio Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools